Incidence and relative risk of peripheral neuropathy in cancer patients treated with eribulin: a meta-analysis.

ABSTRACT:

Background

Eribulin is a microtubule inhibitor, which is approved for the treatment of breast cancer. Peripheral neuropathy has been reported in the studies of eribulin, but the incidence and relative risk (RR) of eribulin-associated peripheral neuropathy varied greatly in cancer patients. The purpose of this meta-analysis was to determine the overall incidence and RR of eribulin-associated peripheral neuropathy in cancer patients.

Materials and methods

Pubmed database and Embase and abstracts presented at the American Society of Clinical Oncology (ASCO) meetings were systematically reviewed for primary studies. Eligible studies included prospective clinical trials and expanded access programs of cancer patients treated with eribulin. Statistical analyses were performed to c

SUBMITTER: Peng L 

PROVIDER: S-EPMC5762380 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature